CVD legislation news
Texas lawmakers once again mull controversial bill based on SHAPE cardiac-screening proposal
The Heart Attack Prevention Bill has been presented in the Texas legislature earlier this month. The bill mandates “private insurance companies to cover the cost of cardiac screening in people at intermediate risk of a cardiac event.” The bill is very similar to “the controversial Screening for Heart Attack Prevention and Education (SHAPE) task-force recommendations calling for blanket screening for subclinical atherosclerosis” that was rejected last year. The author of the two bills is representative René O Oliveira who just had CABG surgery.
CVD drug news
FDA postmarketing surveillance data show no cancer risk with ezetimibe
Good news for manufacturers of cholesterol-lowering drug Zetia (ezetimibe). US FDA postmarketing surveillance data indicate that ezetimibe use is not associated with cancer risk. This is true whether ezetimibe is used alone or in combination with Vytorin (simvastatin). The two drugs are produced by Merck/Schering-Plough.
CVD population news
Heart Failure Before Age 50 Substantially More Common in Blacks
NIH News reports that as many as 1 in 100 African American adults develop heart failure before the age of 50. This is 20 times higher than the rate reported in whites. The disease is linked it untreated risk factors such as high blood pressure, chronic kidney disease, and obesity that started 10 to 20 years earlier. These are the findings of the observational study Coronary Artery Risk Development in Young Adults study (CARDIA) and will bepublished in the March 19 issue of the New England Journal of Medicine.
CVD guidelines news
New Guidelines on Interpretation and Reporting of CCTA
New guidelines for the interpretation and reporting of coronary computed tomographic angiography (CCTA) studies will be published in the March/April 2009 issue of the Journal of Cardiovascular Computed Tomography. The guidelines were developed by the Society of Cardiovascular Computed Tomography (SCCT).
CVD clinical trial news.
CAPTIVATE published: Trial stopped early, and pactimibe development discontinued based on IVUS results
CAPTIVATE stands for Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects. The 2-year trial was discontinued after 15 months when the drug pactimibe did not show any benefit or effect on thickness on maximum carotid intima-media thickness (IMT). The results of the trial have now been published Journal of the American Medical Association.
CVD innovation news
Brain surgery on Monday, home on Tuesday
A new, less invasive form of surgery can now repair life-threatening aneurysms of the brain. A new generation of neurologists use catheter technology to “repair aneurysms, open clogged arteries, extract blood clots and repair blood vessel malformations in the brain.” The catheter, a thin tube, is inserted in an artery in the patient’s leg and guided up to the brain. The technique is less invasive and presents less risks that conventional brain surgery which involves opening the skull.
Photo credit: stock.xchng